Perspective Therapeutics (CATX)
:CATX
Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$4.20
-$0.13(-3.36%)
At close: 4:00 PM EST
$4.20
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.53M
Market Cap
$486.50M
Enterprise Value$261.98M
Total Cash (Recent Filing)$144.74M
Total Debt (Recent Filing)$1.63M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding113,933,430
10 Day Avg. Volume952,717
30 Day Avg. Volume1,532,342
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue311.51
Enterprise Value/Gross Profit-187.26
Enterprise Value/Ebitda-4.22
Forecast
1Y Price Target
$12.91Price Target Upside207.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$687.43K
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst's Buy recommendation and a raised price target signal professional confidence in the company's clinical progress and potential future valuation upside.
Balance Sheet And Manufacturing CapabilityA strong pro forma cash balance combined with owned manufacturing capacity provides a multi-year operational runway and the potential to monetize surplus production or attract strategic partners.
Clinical Safety And Competitive PositioningPb-212-VMT-α-NET has shown a favorable safety and tolerability profile with no dose-limiting toxicities or treatment-related discontinuations, distinguishing it from a competing program and encouraging clinician interest.
Bears Say
Clinical And Regulatory RiskNegative clinical results or regulatory delays for the lead asset could materially weaken investor confidence and pressure the stock's valuation.
Efficacy And Safety Comparability ConcernsReported objective response rate was lower than a competing asset and lingering safety issues such as potential hair loss or kidney effects require larger studies, which may intensify investor scrutiny.
Financing And Dilution RiskRecent equity offerings and high cash burn increase dilution risk and the likelihood of further fundraising that could expand the fully diluted share count.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $486.50M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 19 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Mar 16, 2026. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.363 by -$0.147.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 113,933,430 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.363. Following the earnings report the stock price went down -5.172%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.91 (207.36% Upside)
$12.91 (207.36% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 34.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.33%
12-Months-Change
Fundamentals
Return on Equity
-41.27%
Trailing 12-Months
Asset Growth
-21.64%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$12.91
▲(207.36% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
5.94% Mutual Funds
0.26% Other Institutional Investors
82.38% Public Companies and
Individual Investors